STELARA® DELIVERS RAPID EFFICACY IN CD
Take a look at our results from different clinical trials
UNITI-1 AND UNITI-2 ASSESSED THE EFFICACY AND SAFETY OF STELARA® SINGLE-DOSE IV INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE2,3
IN CD, STELARA® DELIVERS... RAPID EFFICACY FROM A SINGLE IV DOSE
Significantly more patients achieved clinical response with 1 dose of STELARA® vs. placebo IV†3
RAPID RESPONSE IN PATIENTS WITH MODERATE OR SEVERE CROHN'S DISEASE WHO FAILED CONVENTIONAL THERAPY†3
†Patients who have failed conventional therapy comprised biologic-naïve patients and those who had not previously demonstrated inadequate response or intolerance to 1 or more anti-TNF antagonist therapies.
IN CD, STELARA® DELIVERS...A HIGH PERCENTAGE OF RESPONDERS
CLINICAL RESPONSE AT WEEKS 3, 6, AND 8 AFTER STELARA® IV INDUCTION3
Component not published? componentType is undefined.
* Long-term remission is considered a target of ideal treatment in the clinical management of ulcerative colitis (UC).1
BL: Baseline; BWT: Bowel wall thickness; CD: Crohn’s disease; CDAI: Crohn's Disease Activity Index; IUS: Intestinal ultrasound; LTE: Long-term extension; mITT: Modified intention-to-treat; SC: Subcutaneous; SES-CD: Simple Endoscopic Score for Crohn’s disease; T2T: Treat-to-target; TNF: Tumour necrosis factor; UC: Ulcerative colitis.
References
- Danese S et al. Dig Dis 2019;37:266-283.
- Hanauer SB et al. J Crohns Colitis 2020;14:23-32.
- Feagan BG et al. N Eng J Med 2016;375:1946-1960.
- Danese S et al. DOP13 presented at European Crohn’s and Colitis Organisation (ECCO) 15th Congress, 12–15 February 2020, Vienna, Austria.
- ClinicalTrials.gov: NCT03107793. Available at https://clinicaltrials.gov/ct2/show/NCT03107793. Accessed January 2021.
- Kucharzik T et al. DOP10 presented at European Crohn’s and Colitis Organisation (ECCO) 15th Congress, 12–15 February 2020, Vienna, Austria.
PRESCRIBING INFORMATION
ADVERSE EVENTS REPORTING
